Shamburg News · 8-K filed Nov 9, 2026, 4:08 PM EST
Larimar Therapeutics Completes Rolling BLA Submission for Nomlabofusp in Friedreich's Ataxia
LRMR · Larimar Therapeutics, Inc.
- Earnings
- Other event
- Reg FD disclosure
- Materiality: high
Larimar Therapeutics, Inc. announced on November 9, 2026 that it completed its rolling Biologics License Application submission to the FDA seeking accelerated approval of nomlabofusp for Friedreich's ataxia. In an updated slide presentation, the company disclosed preliminary, unaudited cash, cash equivalents and marketable securities of approximately $128.7 million as of September 30, 2026, subject to completion of its quarter-end financial close. The company stated that its Q3 2026 financial close and review are ongoing and could change that figure.
Source: SEC EDGAR, Form 8-K, Items 2.02, 8.01, 9.01, accession 0001193125-26-453586.
Written from the filing by Shamburg Markets. Figures are as reported by the company.